KR970702054A - 헬리코박터 파이로리에 기인한 위장 기능장해 치료를 위한 스피라마이신의 용도(use of spiramycin for treating gastrointestinal disorders caused by h. pylori) - Google Patents

헬리코박터 파이로리에 기인한 위장 기능장해 치료를 위한 스피라마이신의 용도(use of spiramycin for treating gastrointestinal disorders caused by h. pylori)

Info

Publication number
KR970702054A
KR970702054A KR1019960705982A KR19960705982A KR970702054A KR 970702054 A KR970702054 A KR 970702054A KR 1019960705982 A KR1019960705982 A KR 1019960705982A KR 19960705982 A KR19960705982 A KR 19960705982A KR 970702054 A KR970702054 A KR 970702054A
Authority
KR
South Korea
Prior art keywords
spiramycin
treatment
pylori
pct
helicobacter pylori
Prior art date
Application number
KR1019960705982A
Other languages
English (en)
Inventor
에릭 티. 포르팽
스벤-에릭 라르센
Original Assignee
프랑소와즈 로조아
롱프랑 로라 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프랑소와즈 로조아, 롱프랑 로라 소시에테 아노님 filed Critical 프랑소와즈 로조아
Publication of KR970702054A publication Critical patent/KR970702054A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

헬리코박터 파이로리(Helicobacter pylori)를 수반하는 위장 기능 장해의 예방 또는 치료용 약제의 제조를 위한, 메트로니다졸과 임의로 배합된 스피라마이신의 용도가 기술됨.

Description

헬리코박터 파이로리에 기인한 위장 기능장해 치료를 위한 스피라마이신의 용도(USE OF SPIRAMYCIN FOR TREATING GASTROINTESTINAL DISORDERS CAUSED BY H. PYLORI)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 헬리코박터 파이로리(Helicobacter pylori)를 수반하는 위장 기능 장해의 예방 또는 치료용 약제의 제조를 위한, 임의로 메트로니다졸과 배합된 스피라마이신의 용도.
  2. 항-궤양제 치료 전, 후 또는 동시에 수행되는 헬리코박터 파이로리를 수반하는 위장 기능 장해의 예방 또는 치료용 의약품 제조를 위한, 임의로 메트로니다졸과 배합된 스피라마이신의 용도.
  3. 청구항 1 또는 2에 따른 용도를 위한, 임의로 매트로니다졸과 배합된 스피라마이신을 함유하는 약학 조성물.
  4. 청구항 3에 있어서, 항-궤양제 및 스피라마이신을 임의로 매트로니다졸과 함께 함유하는 약학 조성물.
  5. 청구항 4에 있어서, 항-궤양제가 제산제, 항-H2제 및 양성자 펌프 억제 제중에서 선택되는 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960705982A 1994-04-25 1995-04-24 헬리코박터 파이로리에 기인한 위장 기능장해 치료를 위한 스피라마이신의 용도(use of spiramycin for treating gastrointestinal disorders caused by h. pylori) KR970702054A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9404952A FR2718965B1 (fr) 1994-04-25 1994-04-25 Nouvelle application thérapeutique de la spiramycine.
FR94/04952 1994-04-25
PCT/FR1995/000533 WO1995028943A1 (fr) 1994-04-25 1995-04-24 UTILISATION DE LA SPIRAMYCINE DANS DES DESORDRES GASTROINTESTINAUX DUS A $i(H. PYROLI)

Publications (1)

Publication Number Publication Date
KR970702054A true KR970702054A (ko) 1997-05-13

Family

ID=9462476

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960705982A KR970702054A (ko) 1994-04-25 1995-04-24 헬리코박터 파이로리에 기인한 위장 기능장해 치료를 위한 스피라마이신의 용도(use of spiramycin for treating gastrointestinal disorders caused by h. pylori)

Country Status (16)

Country Link
US (1) US6162792A (ko)
EP (1) EP0758245B1 (ko)
JP (2) JP3937448B2 (ko)
KR (1) KR970702054A (ko)
CN (1) CN1147204A (ko)
AT (1) ATE234619T1 (ko)
AU (1) AU2412795A (ko)
BR (1) BR9507848A (ko)
CA (1) CA2188697A1 (ko)
DE (1) DE69529981T2 (ko)
DK (1) DK0758245T3 (ko)
ES (1) ES2194907T3 (ko)
FR (1) FR2718965B1 (ko)
NO (1) NO311285B1 (ko)
PT (1) PT758245E (ko)
WO (1) WO1995028943A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN190017B (ko) 1999-01-25 2003-05-31 Panacea Biotech Ltd
US6576625B2 (en) 2001-03-16 2003-06-10 Panacea Biotic Limited Targeted vesicular constructs for cytoprotection and treatment of H. pylori infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0375068A1 (en) * 1988-12-23 1990-06-27 Gist-Brocades N.V. Combining bismuth compounds and tetracyclines

Also Published As

Publication number Publication date
EP0758245B1 (fr) 2003-03-19
JPH09512262A (ja) 1997-12-09
CA2188697A1 (fr) 1995-11-02
US6162792A (en) 2000-12-19
JP3937448B2 (ja) 2007-06-27
BR9507848A (pt) 1997-09-16
PT758245E (pt) 2003-08-29
NO964252D0 (no) 1996-10-07
DK0758245T3 (da) 2003-07-07
AU2412795A (en) 1995-11-16
DE69529981D1 (de) 2003-04-24
NO311285B1 (no) 2001-11-12
JP2007091761A (ja) 2007-04-12
FR2718965A1 (fr) 1995-10-27
WO1995028943A1 (fr) 1995-11-02
DE69529981T2 (de) 2003-12-04
EP0758245A1 (fr) 1997-02-19
ES2194907T3 (es) 2003-12-01
CN1147204A (zh) 1997-04-09
FR2718965B1 (fr) 1996-05-24
ATE234619T1 (de) 2003-04-15
NO964252L (no) 1996-10-07

Similar Documents

Publication Publication Date Title
KR950007868A (ko) 항궤양제 및 헬리코박터·피롤리의 정착저해제
BR0212019A (pt) Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
FI974268A0 (fi) Flavanolignaanien käyttö lääkkeiden, joilla on lisääntymistä torjuvaa vaikutusta kohdussa, munasarjoissa ja rintarauhasessa, valmistamiseksi
BR0110420A (pt) Agonistas muscarìnicos
ES2155093T3 (es) Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa).
ATE284698T1 (de) Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten
ATE293451T1 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
AU4130196A (en) Methods of treating migraine
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
KR970702054A (ko) 헬리코박터 파이로리에 기인한 위장 기능장해 치료를 위한 스피라마이신의 용도(use of spiramycin for treating gastrointestinal disorders caused by h. pylori)
MA22343A1 (fr) Compositions type massepain, contenant du psyllium
DE3875349D1 (de) Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie.
NO20005588L (no) Inhibisjon av Helicobacter Pylori proliferasjon
AUPP325398A0 (en) Improved method for eradicating h. pylori
BR9908838A (pt) Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite
GB2412066A (en) Method of reducing toxicity of anticancer agents
KR900017599A (ko) 종양 치료용 약학 조성물
EP1051994A3 (en) 5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine
ZA979906B (en) Synergistic gold-containing compositions.
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
KR910014121A (ko) 위궤양 및 미란 치료용인 시메티딘-피렌제핀 제제
DE69736955D1 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen
KR960705553A (ko) 원하지 않는 고통을 멈추기 위한 니트로글리세린의 투약 방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid